98%
921
2 minutes
20
Background: The prevalence of vitiligo has been reported to range from 0.1% to 8% worldwide, and vitiligo has been linked to some autoimmune and non-autoimmune diseases. This study aimed to estimate the prevalence of vitiligo and associated comorbidities in adults in Shanghai.
Methods: A community-based cross-sectional survey was conducted among 9,114 adults (4,288 males) in a community of Shanghai between October 2009 and January 2010. Face-to-face interviews were conducted at the home of each participant, and all respondents had their skin examined by dermatologists. The risks of comorbidities associated with vitiligo were evaluated by multiple logistic regression analysis.
Results: The estimated prevalence of vitiligo was 0.91%, and the standardized (age-adjusted) prevalence was 0.67%. Prevalence increased with age from 0.20% in 18-30 years to 1.59% in the 71-80 years age group. The presence of vitiligo was associated with increased risks of atopic dermatitis [adjusted odds ratio (aOR) =2.49; 95% confidence interval (95% CI): 1.46-4.23], urticaria (aOR =1.83; 95% CI: 1.11-3.04). and coronary heart disease (aOR =1.88; 95% CI: 1.03-3.41), although the association with coronary heart disease was only identified in subjects who were aged ≥60 years or overweight.
Conclusions: The prevalence of vitiligo in Shanghai was comparable to that seen in previous studies and increased with age. Vitiligo was associated with increased risks of atopic dermatitis, urticaria, and coronary heart disease in adults.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.21037/apm-21-1738 | DOI Listing |
Medicine (Baltimore)
September 2025
Department of Oncology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Numerous observational studies have suggested links between sex hormones and various autoimmune diseases (ADs). However, the causality of these associations remains uncertain. This study employs Mendelian randomization (MR) analysis to investigate the causal relationship between sex hormones and ADs risk.
View Article and Find Full Text PDFPLoS One
September 2025
Geriatric Medicine Center, Department of Nursing, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Background: In recent years, with the expanding use of novel therapeutics such as immune checkpoint inhibitors and monoclonal antibodies, reports of drug-induced vitiligo have been increasing. This study aimed to identify drugs associated with vitiligo using the FDA Adverse Event Reporting System (FAERS).
Methods: A retrospective disproportionality analysis was performed on FAERS reports from the first quarter of 2004 to the fourth quarter of 2024.
J Dermatolog Treat
December 2025
Pfizer Inc, New York, NY, USA.
Objectives: Vitiligo is an autoimmune disease resulting in skin depigmentation and individuals report substantial psychosocial burden. However, vitiligo-related quality of life impacts appear heterogeneous and may be influenced by social determinants of health. This cross-sectional survey aimed to describe characteristics and vitiligo-related quality of life impacts among adults in Brazil, China, India, and South Africa.
View Article and Find Full Text PDFJ Dermatol
September 2025
Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Few population-based studies have investigated the association between melanoma and autoimmune diseases in Asian populations. We conducted a population-based cross-sectional study using the South Korean National Health Insurance database to investigate the association between melanoma and autoimmune diseases in Asian individuals. Melanoma patients were identified, and birth year and sex matched controls were randomly selected at a 1:10 ratio.
View Article and Find Full Text PDFWorld J Urol
August 2025
SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
Urological cancers-including prostate, bladder, renal, and testicular cancers-are commonly treated with surgery, chemotherapy, radiation therapy, and immunotherapy. While these therapies improve survival outcomes, they often induce significant dermatological side effects that impair patients' quality of life and treatment adherence. This review synthesizes current literature on the prevalence, mechanisms, and psychosocial consequences of dermatological toxicities associated with urological cancer treatments.
View Article and Find Full Text PDF